diagnost tool
price close busi may
fast-grow compani anim health
diagnost seek take modest us market share
gain expand intern significantli time
new product new market target lay
plan growth buy pt
remain posit attend compani analyst day interact
sever member abax manag team think deliv solid
updat highlight announc major new product launch come growth
margin target addit visibl intern
expans plan narrowli trim expect level-set
pace quarter believ de-risk near-term setup continu like
new product launch also given scarciti valu
thesi anim health well valid post week zts-abax deal
announc last stand small pure-play anim health diagnost
believ attract takeout candid buy rais pt
revenue margin target initi revenu target gm
om suggest revenue compound-annual-growth-rate gm
om expansion/year view revenu target readili
achiev context model rev gm om
major new product add announc launch
element urin sediment analyz element immuno-diagnost analyz
element fecal imag analyz peg
target launch respect
urin announc launch element sediment urinalysi instrument
peg market first mover
sedivu abax follow vetscan sa believ strong earli traction
abax confirm us market real time
think get fair share global peg time
element announc launch element plu highli sensit
immuno-assay base platform multiplex target target test
launch infecti diseas panel lyme anaplasma ehrlichia thyroid panel
allergi ige panel canine/felin panel fiv felv work
co-bas diagnost array system target test tat minut
fecal announc launch element autom fecal imag platform
fecal pathogen look combin artifici intellig relat softwar
target launch size element tam
full visibl intern expans groundwork seem
place plan initi ou push make major push
call indic plan partner exclus us distributor
market outsid north america consist think
believ help meaning expand busi
guidanc tweak de-risk near-term setup view tweak
baselin revenue guid gm flat due ovp
initi quarterli revenue target balanc us
us continu expect revenue growth consum
growth imag partial off-set y/i ovp
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
new product
financi target lay path double-
digit growth buy rais pt
consist expect deliv solid updat highlight
announc major new product launch come growth margin target
offer addit visibl intern expans
plan also narrowli trim expect level-set
pace quarter view posit de-risk near-term setup
continu like new product launch also given
scarciti valu thesi anim health small pure-play anim health
diagnost believ compani like attract takeout candid
like anim health leader mar inc among other reiter
buy rais pt use multipl revenu estim
discount back year discount rate million share
target double-digit top gain margin encourag
initi revenu target impli
compound-annual-growth-rate revenu base indic new product
launch expect contribut growth balanc driven
legaci product growth intern expans impli hska compound-annual-growth-rate
growth consum y/i growth digit imag
also initi gross margin oper margin target
respect impli gm om expans
per year context model rev gm om
think crux gm expans driven modest price realiz
on-going growth higher-margin consum driven hska subscript
figur initi encourag target revenu gross oper margin
revenu target contempl growth consum
segment confid achiev target market share growth
buy unchang target price may
diagnost tool
new subscript corpor group win growth util
well visit annual price increas rais reset model start
price first rais sinc growth new instrument test launch
continu market growth anim diagnost
look drive per year growth digit imag segment new
extend mainten agreement revenu come board new
product launch includ slate hub sonosl dentisl
sd basic/sd dental dr small anim
telemedicin servic new product launch digit imag seek
address veterinarian recommend pet owner monitor anim
dental care pursu clinic indic digit radiograph among thing
major new product announc kick
announc launch major new product element urin
sediment analyz element immuno-diagnost analyz element
fecal imag analyz peg
target launch respect think
signific new product without competit
market leader abaxi earlier week agre acquir
element urin sediment chemistri analyz announc
plan launch element urin sediment chemistri analyz
directli compet idxx sedivu abax vetscan sediment analyz
consid zero-sum game market first mover
sedivu abax follow vetscan sa believ strong earli traction
abax confirm us market real
time think get fair share global peg
time indic sediment analyz place
market thu far recent abax urin
sediment exam conduct annual element expect price
subscript program appear us
afford good number vet practic hksa peg urin sediment
chemistri test market opportun
element limit high sensit immunoassay announc
plan launch element high sensit immunodiagnost multiplex analyz
sign global exclus vet anim health licens
element made equiti invest manufactur instrument
element lower cost smaller faster offer higher sensit hska
multiplex capabl test card believ drive lower
commun target test tat minut recal abaxi previous
call intent launch high sensit vetscan well
test menu expect includ infecti diseas panel thyroid panel
allercept ige panel canin felin annual panel see target
believ futur allercept panel may spur adopt allercept therapi
shot therapi drop seek provid lifetim manag pet allergi
buy unchang target price may
diagnost tool
figur consid high sensit immunodiagnost market
element autom fecal imag announc plan launch
element microscopi fecal imag ai softwar platform expect
launch element seek identifi parasit includ
roundworm hookworm whipworm tapeworm giardia flukeworm directli
compet snap fecal antigen test present plan launch
push quarter believ identifi
diagnos parasit imag techniqu gold standard
remain skeptic accuraci fecal antigen test method heska
believ autom fecal imag ai softwar platform improv manual
often unpleas process handl fecal sampl estim
manual fecal flotat visual exam perform poc set year
element expect price peg
market opportun note hska strategi launch
autom bench-top instrument doubl strategi
promot hand-held rapid assay
cloud plan pursu cloud data ai expans
cloud bank set launch integr famili share
softwar ai capabl span digit imag poc test urin sediment
fecal imag test plan view share store analyz patient data
may leverag next year use program
intern time accumul data studi
exist product line expans help pad near-term growth offer
bridg larger product come
element coag launch gener coag blood-typ analyz
alreadi place instrument subscript agreement
rep visit custom instrument upgrad custom given
buy unchang target price may
diagnost tool
opportun extend subscript agreement month thu
custom month left agreement decid upgrad add
element coag analyz instrument matter opportun
extend leas month result net pickup month
figur alreadi place second-gen coag analyz sinc launch
element plan launch new element dri chemistri analyz
custom next-gen chemistri analyz run
sampl time featur compact form factor user interfac includ
intern lot barcod serv anoth opportun rep renew extend
subscript agreement believ element cater larg user
specialti hospit corpor account given high-volum natur box
often time consist high qualiti account particularli larg corpor
account often acquir build addit clinic year
figur plan launch next-gen element chemistri analyz
buy unchang target price may
diagnost tool
heartworm solostep test reformul announc push
delay plan launch heartworm solostep test given still need
collect addit sampl complet usda trial indic need
total sampl fulfil regulatori requir specimen collect
complic given vari sever incid heartworm new heartworm
offer low-cost later flow test cog improv seek
offer simpl solut overserv heartworm market look revers
heartworm test growth time intend cross sell
test merck tri-heart treat test
provid addit detail regard plan expand outsid north
america howev leav import detail desir expect learn
much come quarter
indic analyst day target preliminari intern launch
australia new zealand target main intern expans
european region
indic make go/no decis expect provid
announc time pursu intern expans via
joint ventur jv partnership intend launch independ lack
visibl independ launch scenario would believ
independ launch highli like event
recal announc late april hire jason aroesti met
analyst day evp intern diagnost assum respons
compani intern expans posit initi impress mr
aroesti respons global sale market
point-of-car busi siemen mr aroesti base europ year
call indic plan partner exclus us distributor
market outsid north america consist
think believ help meaning expand busi
confirm counterparti joint ventur
propos analyst day provid addit color around time
intern launch target geograph area
sign non-bind letter intent intern invest back
januari conduct intern review determin suitabl
plan agreement market revis jv propos may
continu evalu suitabl agreement joint ventur propos
includ global anim health compani would featur major
owner oper agreement would provid global logist
support arrang intend launch intern busi
independ jv form year-end
target australia new zealand preliminari intern expans
australia new zealand among initi target given higher
pet per capit spend canine- au vs us felin au vs
us establish logist channel recept hska reset subscript
model small exist instal base element dc instrument
parti agenc estim australia new zealand
buy unchang target price may
diagnost tool
evalu suitabl variou ou market base
market recept subscription-bas model
stabl currenc inflat govern econom system
robust contract properti right system
languag cultur eas entri
strong economi lower major recess risk
intend expand sale forc field rep start
june ramp throughout current sale team includ poc
laboratori rep poc imag rep custom support rep corpor
sale allergi rep new rep come on-board parallel new product
launch look correl breadth offer servic number
rep field note ratio sale rep sale
rep doesnt chang materi given jump rep
expans support bottom-up sale approach directli target potenti client
narrowli trim guid initi quarterli target
moder lower bar baselin revenu trim
revenu guid due ovp initi quarterli revenue
target balanc suggest us
us expect gm flat full year revenue growth
blood consum imag partial off-set
ovp provid expect quarterli cadenc assum
sequenti declin revenu follow acceler back half see
figur expect rev vs prior
vs prior vs prior
om includ hska revenu
growth target consum growth subscript market share
growth digit imag ovp revenu ovp segment
expect expens higher y/i expens
higher expens higher compar level
buy unchang target price may
diagnost tool
figur narrowli trim outlook initi quarterli revenu target impli top-lin acceler back half
model primarili get line manag guidanc lower revenue
estim maintain revenue estim
rais estim
introduc revenu estim
trim ep ep
ep estim consensu larg expect higher
oper expens rel consensu account new sale forc expans
like uptick spend note model line heska
margin target think consensu estim appear high given
manag commentari present analyst day believ
near-term earn growth stori rather market share stori
particularli outsid unit state model gm
respect model gm manag
gm target think estim may prove conserv
indic reset rental custom retent rate note
level consist idxx level rang histor
abax level current estim
indic subscrib use antech lab mar inc
primari refer lab use
gone subscrib end end
secur subscript win ytd target total
subscript win
look drive win free stand hospit
corpor hospit similar petvetcar agreement
recent rais start price reset model first start
buy unchang target price may
diagnost tool
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
buy unchang target price may
diagnost tool
buy unchang target price may
diagnost tool
